Beam

Catalent Experts to Co-Host Workshops on Supply Chain Management at Upcoming Global Clinical Supplies Group Conference

Retrieved on: 
Thursday, April 13, 2023
Augsburg University, VAT, Clinical trial, Bone marrow, Fort Hays, Transport, Fort Hays State University, GCSG, Economics, EDT, Beam, Business administration, Patient, Case management, Newborn Emergency Transport Service, Therapy, Clinical, Conference, Pharmaceutical industry, Management, Science, Catalent, Biology

SOMERSET, N.J., April 13, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that two of its clinical supply experts are to co-host workshop sessions at the upcoming Global Clinical Supplies Group (GCSG) Conference, to be held at the Hyatt Regency Grand Cypress Hotel, Orlando, Florida, on April 23 - 26, 2023.

Key Points: 
  • Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that two of its clinical supply experts are to co-host workshop sessions at the upcoming Global Clinical Supplies Group (GCSG) Conference, to be held at the Hyatt Regency Grand Cypress Hotel, Orlando, Florida, on April 23 - 26, 2023.
  • SOMERSET, N.J., April 13, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that two of its clinical supply experts are to co-host workshop sessions at the upcoming Global Clinical Supplies Group (GCSG) Conference, to be held at the Hyatt Regency Grand Cypress Hotel, Orlando, Florida, on April 23 - 26, 2023.
  • Hosting the session will be Trish Demko, Catalent's Director of Case Management Services, alongside Beth Gardner, Senior Director of Patient Supply at Beam Therapeutics.
  • Her experience spans two decades of successfully managing global supply chains across a range of industries, and she holds a bachelor's degree in business administration and supply chain from Fort Hays State University, Kansas.

Beam Global Receives Multi-Million Dollar Battery Module Order for an Industrial Product Line

Retrieved on: 
Tuesday, April 11, 2023
EV, Beam Suntory, GHG, Temperature, McKinsey & Company, EPA, Beam, SAN, AGV (train), Artificial intelligence, Robotics, ASRS, Automation, Renewable energy

The battery modules include Beam’s patented thermal management technology for superior safety, higher energy density, broader operating temperature range and longer life.

Key Points: 
  • The battery modules include Beam’s patented thermal management technology for superior safety, higher energy density, broader operating temperature range and longer life.
  • “Electrification and robotics in factories, warehouses and industrial settings are making organizations’ supply chains cleaner, safer and more efficient,” said Beam Global CEO Desmond Wheatley.
  • “Beam AllCell energy storage solutions are the ideal choice for the superior performance that our customers demand and deliver.
  • Industrial automation and industrial electrification are key trends shaping the global energy transition to cleaner manufacturing and a cleaner supply chain.

JENNIFER LOPEZ LAUNCHES DELOLA SPRITZES & COCKTAILS

Retrieved on: 
Tuesday, April 4, 2023
Taste, Paloma, Lion, RTD, Food, Partnership, Wine & Spirits, HOUSE, Education, Friends, Southern Glazer's Wine and Spirits, Sugar, Jenna, Woman, SRP, Hibiscus, ROSA, Amaro, Beam, Ice, Rock, Tequila, Restaurant, Beam Suntory, Citrus, Family, Glass, Wine, Liquor, Interior design

NEW YORK, April 4, 2023 /PRNewswire/ -- Jennifer Lopez is proud to announce the creation of THE HOUSE OF DELOLA LLC, a company she founded to launch unique, mixology-level ready-to-enjoy cocktails designed for elegant, effortless entertaining as part of a thoughtful lifestyle. Delola offers premium spirit-based, full-flavored, crafted cocktails that are made with natural botanicals, are gluten free and lower calorie than traditional cocktails, and are served in beautifully-crafted glass bottles designed for easy sharing when entertaining friends and family – just open, pour over ice and serve.

Key Points: 
  • Beam Suntory, a leading global spirits company, is a minority investor in Delola and has been named Delola's global distribution partner.
  • Known for her strong work ethic, Jennifer still prioritizes balance, and between projects she makes time for friends and family.
  • Jennifer was inspired to develop her own refreshing and flavorful spritzes – delicious, spirit-based cocktails free from artificial colors and without all the sugars traditional spritzes can contain, crafted with natural botanicals and about as much alcohol as a glass of wine.
  • Jenna Fagnan, co-founder of Delola stated, "Ken and I have been inspired by Jennifer's hands-on approach to building the Delola business.

Beam Global Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 29, 2023
EV, U.S. Department of Defense Strategy for Operating in Cyberspace, Beam Suntory, Marketing, Internet, Aviation, Veteran, Steel, Cell, Beam, Acquisition, SAN, Engineering, United States Department of the Army, Veterans' affairs, Growth, U.S. Department of Veterans Affairs, Office of Inspector General, Cryptocurrency, Fireworks, Video game, Federal

“The sales, engineering and operations teams at Beam Global are firing on all cylinders and determined to show how much more we can do.

Key Points: 
  • “The sales, engineering and operations teams at Beam Global are firing on all cylinders and determined to show how much more we can do.
  • Gross loss for the quarter ended December 31, 2022 was $0.7 million, or 9% of sales, compared to $0.3 million, or 10% of sales in the same quarter of the prior year.
  • Operating Expenses were $7.1 million for the fourth quarter of 2022, compared to $1.7 million for the same period in the prior year.
  • Those without internet access or unable to pre-register may dial in by calling:
    Please ask to be joined into the Beam Global call.

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Amgen, DNA, Novartis Institute for Tropical Diseases, Drug development, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, CSO, Indian Institute of Science Education and Research, Thiruvananthapuram, Biotechnology, Howard Hughes Medical Institute, Research, Mount Sinai, Biomedical Research, Neuroscience, DSM-IV codes, Acquisition, Novartis, Patient, Hematology, Drug discovery, Cadent, Therapy, Stanley Center for Psychiatric Research at Broad Institute, Genome, Pharmaceutical industry, Beam, Sangamo Therapeutics

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).

Key Points: 
  • CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).
  • Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities.
  • Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
  • “We are thrilled to welcome Gopi to the Beam team during this exciting time as we advance our diverse clinical and earlier-stage pipeline of base editing programs,” said Dr. Ciaramella.

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023
Gene editing, BCMA, Research and development, IND World's Fair Line, Stem cell, Development, Culture, Cancer, Bangladesh Technical Education Board, CD47, Epithelium, ADA, Hepatocyte, State Administrative Expenses, CAR, ISSCR, CD19, Cell, Success, Immune system, Diabetes, Research, CD22, AACR, Lymphoid leukemia, NIH, Patient, ASH, Safety, Letter, Contingency, Retinal pigment epithelium, Serum, Survival, SANA, Autoimmunity, Administration, Immunosuppression, Fusome, Investment, GAAP, Disease, Biotechnology, IND, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Beam

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

Retrieved on: 
Wednesday, March 15, 2023
Conference, Biotechnology, Barclays, Pharmaceutical industry, Self storage, Beam

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, will participate in a fireside chat during the Barclays 2023 Global Healthcare Conference on Thursday, March 16, 2023 at 8:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, will participate in a fireside chat during the Barclays 2023 Global Healthcare Conference on Thursday, March 16, 2023 at 8:30 a.m.
  • ET in Miami, FL.
  • A live webcast will be available in the investor section of the company's website at www.beamtx.com , and will be archived for 60 days following the presentation.

Beam Appoints Technology Executive Kimberly Morgan as Chief Operations Officer

Retrieved on: 
Wednesday, March 8, 2023
John Lewis, Schmidt Futures, Case management, Social impact, Commerce, Public policy, U.S. Chamber of Commerce Building, Public sector, Corporation, Government, Politics, Fintech, Financial management, Television, Management, Renewable energy, Beam

BROOKLYN, N.Y., March 8, 2023 /PRNewswire/ -- Beam – the end-to-end platform that streamlines equitable public benefits administration – today announced Kimberly Morgan as Chief Operations Officer to lead the company's people and processes and advance its mission of bringing dignity to the social safety net. Kimberly brings deep C-suite technology experience, with an emphasis on driving operational excellence by building and empowering great teams. Since 2020, Beam has administered over $200 million to 300,000 families throughout the United States.

Key Points: 
  • Kimberly brings deep C-suite technology experience, with an emphasis on driving operational excellence by building and empowering great teams.
  • Since 2020, Beam has administered over $200 million to 300,000 families throughout the United States.
  • After spending years in financial technology, nonprofit work, and politics, I saw an opportunity to enter the govtech industry and use technology solutions as an avenue to positively impact historically marginalized communities," said Kimberly Morgan, COO at Beam.
  • "Beam's expansion into government is an exciting opportunity for the company to do well by serving the most people," said Margot Kane, Chief Investment Officer at Spring Point Partners and Beam board member.

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 2, 2023
Safety, N-Acetylgalactosamine, MBA, Annual general meeting, FDA, Hypercholesterolemia, IND, Health care, ANGPTL3, Research, PCSK9, Sarepta Therapeutics, American College, University, Blood, Patient, ACC, Liver, Injection, D, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BBA, Medicine, Letter, G&A, LPA, Innovation, Clinical trial, Disease, American College of Cardiology, ASCVD, Cardiovascular disease, Second Half, University of Massachusetts Chan Medical School, United Kingdom, MHRA, Food, R, Acquisition, Beam, Moyamoya disease, Pharmaceutical industry, Vaccine, Cryptocurrency, Mouse, Verve, Vertex

BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • VERVE-101 is initially being developed for the treatment of heterozygous familial hypercholesterolemia (HeFH), a genetic subtype of atherosclerotic cardiovascular disease (ASCVD).
  • Verve continues to enroll patients into the heart-1 clinical trial in New Zealand and the United Kingdom (UK).
  • Prior to joining Verve, she led the human resource functions at Sarepta Therapeutics and earlier, led human resources at Dyax, prior to its acquisition by Shire.
  • Collaboration Revenue: Collaboration revenue was $1.0 million for the quarter ended December 31, 2022, and $1.9 million for the year ended December 31, 2022.

AEP NAMES MARSH VICE PRESIDENT OF SAFETY AND HEALTH

Retrieved on: 
Wednesday, March 1, 2023
Carbon, Knowledge, Safety, American Electric Power, Beam, Organization, Indiana Michigan Power Center, Safety and Health, Electricity, AEP, Multimedia, Energy, West Virginia University, Virginia University, Management, Nursing, Health, Texas Panhandle

COLUMBUS, Ohio, March 1, 2023 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has named Michelle Marsh vice president, Safety and Health, effective March 4.

Key Points: 
  • COLUMBUS, Ohio, March 1, 2023 /PRNewswire/ -- American Electric Power (Nasdaq: AEP) has named Michelle Marsh vice president, Safety and Health, effective March 4.
  • "At AEP, the safety and well-being of our customers, employees and business partners is a core value," said Beam.
  • "Michelle's vast background and breadth of knowledge in workplace safety and health make her a confident choice to lead our efforts to achieve Zero Harm.
  • She first joined AEP in 2007 as an environmental, safety and health consultant and has held roles of increasing responsibility in the Safety and Health and Transmission organizations.